Cognition gets its Series A

Biotech start-up Cognition Therapeutics has rounded up $1.2 million for its Series A. Cognition hopes to develop a new therapy for Alzheimer's disease. New York-based Ogden CAP LLC led the round with M5Invest Partners, Innovation Works and Pittsburgh Life Sciences Greenhouse adding to the round with individual investors. Report